Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel.

ABSTRACT:

Aims

Clinical decision making is challenging in men with metastatic prostate cancer (mPC), as heterogeneity in treatment options and patient characteristics have resulted in multiple scenarios with little or no evidence. The South East Asia Expert Panel 2019 addressed some of these challenges.

Methods

Based on evidence in the literature and expert interviews, 19 statements were formulated for key challenges in the treatment of men with castration-sensitive and -resistant prostate cancer in clinical practice. A modified Delphi process was used to reach consensus among experts in the panel and develop clinical practice recommendations.

Results

The majority of the panel preferred a risk-based stratification and recommended abiraterone or enzalutamide as first-line therap

SUBMITTER: Schutz FAB 

PROVIDER: S-EPMC7905487 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature